Table 3 Clinical trials of CAR NK cell therapies around the world
Number | Disease | Binding epitope | Location | Start time | Study completion | Number enrolled | Status |
|---|---|---|---|---|---|---|---|
NCT03692767 | B cell lymphoma | CD19 | NA | 2019/3/1 | 2021/11/1 | 9 | Not yet recruiting |
NCT03690310 | B cell lymphoma | CD22 | NA | 2019/3/1 | 2021/11/1 | 9 | Not yet recruiting |
NCT03824964 | B cell lymphoma | CD19/CD22 | NA | 2019/2/1 | 2021/1/1 | 10 | Not yet recruiting |
NCT03056339 | B lymphoid malignancies | CD19 | Texas, USA | 2017/6/21 | 2022/6/1 | 36 | Recruiting |
NCT03692663 | Prostate cancer | PSMA | NA | 2018/12/1 | 2021/12/1 | 9 | Not yet recruiting |
NCT03692637 | Epithelial ovarian cancer | Mesothelin | NA | 2019/3/1 | 2021/11/1 | 30 | Not yet recruiting |
NCT03383978 | Glioblastoma | HER2 | Frankfurt, Germany | 2017/12/1 | 2020/8/1 | 30 | Recruiting |
NCT03940833 | Multiple myeloma | BCMA | Jiangsu, China | 2019/5/1 | 2022/5/1 | 20 | Recruiting |
NCT04004637 | NK/T cell lymphoma, ALL | CD7 | Henan, China | 2019/6/1 | 2021/6/1 | 10 | Recruiting |
NCT03941457 | Pancreatic cancer | ROBO1 | Shanghai, China | 2019/5/1 | 2022/5/1 | 9 | Recruiting |
NCT03940820 | Solid tumor | ROBO1 | Jiangsu, China | 2019/5/1 | 2022/5/1 | 20 | Recruiting |
NCT03415100 | Solid tumors | NKG2DL | Guangdong, China | 2018/1/2 | 2019/12/1 | 30 | Recruiting |